Return to the catalog
Tesamorelin
NewIn Stock5mg vial

Tesamorelin

Modified GHRH peptide studied for growth-hormone patterns and abdominal fat research.

For Research Use Only

Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.

1–4 vialsR 550.00
5+ vials — save 27%R 400.00 each

The lower price is applied automatically once your cart holds 5 or more of this vial.

Bacteriostatic water included

99%+ Purity
Extensively Researched
1

About this peptide

Tesamorelin is a modified version of GHRH, the natural signal that tells the pituitary gland to release growth hormone. Its small chemical modification helps make the peptide more stable. Researchers study its effects on normal growth-hormone pulses and on fat stored around the abdominal organs.

Why researchers reach for Tesamorelin

GHRH receptor selectivity

Selectively activates pituitary GHRH receptors.

Visceral fat research

Well-cited in VAT reduction and lipid-profile studies.

Preserves pulsatility

Supports physiological GH pulse patterns in preclinical work.

Key features

  • ≥99% HPLC purity
  • Modified GHRH(1-44) sequence
  • Mass-spec verified
  • Cold-chain dispatch

How it works

Receptor engagement

Binds pituitary GHRH receptors to stimulate GH release.

IGF-1 elevation

Downstream IGF-1 rise observed across research cohorts.

Lipolytic signaling

Referenced in VAT and hepatic-lipid endpoints.

Research dosage guidelines

Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.

RangeReported doseNote
Typical reconstitution2 mL bacteriostatic waterYields 2.5 mg/mL (2500 mcg/mL)
Reported research range1–2 mg/dayReference only

Tracking this compound? Registered researchers can log active Tesamorelin protocols in their private Research Log.

Timing in research protocols

Once daily, conventionally at bedtime to align with the nocturnal growth-hormone pulse.

  • The phase 3 trial (Falutz et al., NEJM 2007) used 2 mg subcutaneously once daily for 26 weeks, with extension data to 52 weeks.
  • Bedtime administration follows GHRH-analogue pharmacology — potentiating the natural night-time growth-hormone pulse — although the trials did not test time of day as a variable.
  • Meal relationship was not systematically studied in the registration programme.
  • Effects reversed on discontinuation in the trials, so the studied pattern is continuous daily dosing rather than short cycles.

Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.

Technical specifications

Sequence
trans-3-hexenoyl-GHRH(1-44)
Molecular weight
5195.8 g/mol
Purity
≥99% (HPLC)
Form
Lyophilized powder
Vial size
5 mg
Storage (lyophilised vial)
Cool, dry and protected from light
Storage (after reconstitution)
2–8°C

Published research

Peer-reviewed literature on Tesamorelin. Links open in a new tab.

Research use notice

Sold for in vitro laboratory research only. Not for human or veterinary use, diagnosis, or therapy.

#GHRH#visceral-fat#lipid

Cart (0)

Your cart is empty